0.08%| Prev Close: | 258.50 |
|---|---|
| Open: | 253.00 |
| Bid: | 249.70 |
| Ask: | 250.00 |
| 1y Target Est: | N/A |
| Beta: | N/A |
| Next Earnings Date: | N/A |
| Day's Range: | 249.20 - 254.00 |
|---|---|
| 52wk Range: | 156.10 - 258.50 |
| Volume: | 28,952 |
| Avg Vol (3m): | 34,482 |
| Market Cap: | N/A |
| P/E (ttm): | N/A |
| EPS (ttm): | N/A |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in CHF.
Headlines
- Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood CancerBusiness Wire(Wed May 15)
- Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCOBusiness Wire(Wed May 15)
- FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung CancerBusiness Wire(Tue May 14)
- FDA Approves ACTEMRA® for Children Living with a Rare Form of ArthritisBusiness Wire(Tue Apr 30)
- News Summary: US flu season helped Roche in 1QAP(Thu Apr 11)
- Severe US flu season helped Roche's Q1 salesAP(Thu Apr 11)
- Swiss drug maker Roche sees Q1 sales riseAP(Thu Apr 11)
- Roche and Isis Pharmaceuticals form alliance for Huntington's diseasePR Newswire(Mon Apr 8)
- Tucson Symposium attracts over 450 global scientists focused on personalized healthcarePR Newswire(Fri Mar 8)
- Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesionsPR Newswire(Tue Feb 26)
- Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic Form of Hives who Failed Standard TherapyBusiness Wire(Sun Feb 24)
- FDA Approves Genentech’s Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast CancerBusiness Wire(Fri Feb 22)
- Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin® for acromegaly and neuroendocrine tumorsPR Newswire(Mon Feb 18)
- RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug CompoundsPR Newswire(Tue Feb 12)
- Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)Business Wire(Thu Jan 31)
Press Releases
- Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood CancerBusiness Wire(Wed May 15)
- Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCOBusiness Wire(Wed May 15)
- FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung CancerBusiness Wire(Tue May 14)
Must Read
- Oil falls below $94 as China manufacturing contractsThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- These beaches have gone to the dogs; lucky pooches lap up the shoreline where they run freeThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- HP's 2nd-qtr report shows signs of further decay but offers hope of recovery; stock soarsThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- HP raises 2013 outlook as Whitman's plan takes holdReuters(1969-12-31T18:59:59GMT-05:00)
- Clearwire, shareholders brace for fight over Sprint bidReuters(1969-12-31T18:59:59GMT-05:00)